Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Current Medical Research and Opinion
Dagmar KubitzaWolfgang Mueck

Abstract

The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of rivaroxaban--a novel, oral, direct Factor Xa (FXa) inhibitor--in healthy elderly subjects. In this single-centre, single-blind, placebo-controlled, parallel-group, dose-escalation study, 48 subjects (aged 60-76 years) were randomized to receive a single oral dose of 30, 40 or 50 mg of rivaroxaban or placebo. Rivaroxaban was absorbed rapidly, reaching peak plasma concentration (C(max)) 4 h after dosing in all groups. Bioavailability, in terms of the area under the plasma concentration-time curve (AUC) and C(max), increased slightly (less than dose proportionally) after administration of rivaroxaban 40 mg compared with 30 mg, but was not increased further with rivaroxaban 50 mg. Rivaroxaban pharmacodynamic effects (inhibition of FXa activity and prolongation of prothrombin time, activated partial thromboplastin time and HepTest) all showed a similar pattern, with maximum inhibition of FXa activity increasing from 68% after rivaroxaban 30 mg to 75% after 40 mg and no further increase with the 50 mg dose. Most adverse events were mild; observed rates were less than placebo for the 30 and 40 mg dose groups, and similar to placebo for 50 mg. No diff...Continue Reading

References

Nov 1, 1994·Annals of Internal Medicine·P S WellsJ Hirsh
Sep 30, 2000·Seminars in Thrombosis and Hemostasis·J FareedR L Bick
Feb 7, 2001·Chest·J AnsellD Matchar
Mar 29, 2001·Clinics in Geriatric Medicine·E M Hylek
Jul 14, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·J HirshUNKNOWN American Heart Association
Jan 14, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Kenneth G MannKathleen Brummel
Jun 20, 2003·Circulation·Richard H White
Jun 24, 2003·Thrombosis Research·Jack Hirsh
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Jan 18, 2006·Journal of Thrombosis and Haemostasis : JTH·B I ErikssonUNKNOWN ODIXa-HIP Study Investigators
Mar 11, 2006·European Heart Journal·Jan HeeringaJacqueline C M Witteman
Dec 30, 2006·Circulation·Wayne RosamondUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 6, 2007·Thrombosis and Haemostasis·Mary J HeebAnnlia Paganini-Hill
Dec 22, 2007·European Heart Journal·Alexander G G Turpie
Feb 26, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Peter L Gross, Jeffrey I Weitz
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators

❮ Previous
Next ❯

Citations

Apr 27, 2013·European Journal of Clinical Pharmacology·Sebastian Harder, Jochen Graff
Jan 24, 2013·Journal of Thrombosis and Thrombolysis·Gwen M Bernacki, Richard C Becker
Apr 19, 2013·Journal of Thrombosis and Thrombolysis·Surekha Maddula, Jack Ansell
Jan 8, 2013·Clinical Pharmacokinetics·Francesco Scaglione
Dec 18, 2010·Nature Reviews. Drug Discovery·Elisabeth PerzbornFrank Misselwitz
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Dec 18, 2013·British Journal of Anaesthesia·H T BenzonR O Bonow
Aug 30, 2011·European Heart Journal·Stefan H Hohnloser, Stuart J Connolly
Feb 23, 2012·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Jean-Pierre Bassand
Apr 30, 2013·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Hein HeidbuchelUNKNOWN European Heart Rhythm Association
Aug 9, 2011·Journal of Cardiovascular Pharmacology·Kenneth Todd MoorePaul Bryan Burton
May 13, 2010·American Journal of Therapeutics·Dhara ChaudhariRohit Arora
Dec 20, 2012·Therapeutic Advances in Chronic Disease·Nicholas B NorgardBenjamin Wee
Jul 20, 2013·International Journal of Emergency Medicine·Patrick GoldsteinEric Wiel
Jun 10, 2010·Drug Design, Development and Therapy·Cecilia BecattiniGiancarlo Agnelli
May 2, 2012·Therapeutics and Clinical Risk Management·Sebastian WerthJan Beyer-Westendorf
Sep 14, 2012·Vascular Health and Risk Management·Mariano A Giorgi, Lucas San Miguel
May 16, 2013·Vascular Health and Risk Management·Antonio Gómez-OutesEduardo Rocha
Oct 23, 2010·Drugs·Hans-Juergen Rupprecht, Ralf Blank
Jul 11, 2012·Hämostaseologie·T HelbingM Moser
May 29, 2014·Vascular Health and Risk Management·Ganesh Nallur Shivu, Nick Ossei-Gerning
Feb 8, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Carlos J Gonzalez-Quesada, Robert P Giugliano
Sep 4, 2013·Clinical Pharmacokinetics·Wolfgang MueckMichael Becka
Nov 16, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Daniel KimLuigi Brunetti
Jan 31, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masayasu MatsumotoUNKNOWN J-ROCKET AF Study Investigators
May 21, 2014·Cardiovascular Drugs and Therapy·A JalotaJ Halperin
Dec 3, 2013·Journal of Thrombosis and Thrombolysis·Reinhold Kreutz
Aug 30, 2014·Clinics in Laboratory Medicine·Lance A WilliamsThomas R Vetter
Jun 28, 2014·Current Neurology and Neuroscience Reports·Michael Levine, Joshua N Goldstein
Aug 30, 2014·Clinics in Laboratory Medicine·Eric AndersonJerrold H Levy
Apr 4, 2014·Emergency Medicine International·Jürgen Koscielny, Edita Rutkauskaite
Mar 22, 2014·Vascular Health and Risk Management·Sylvia HaasAlexander Gg Turpie
Mar 1, 2012·Journal of Medical Economics·Charles Mahan, Alex C Spyropoulos
Sep 12, 2009·Expert Opinion on Therapeutic Patents·Modesto de CandiaCosimo Altomare
May 11, 2011·Expert Opinion on Investigational Drugs·Deepu Alexander, Allen Jeremias

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.